Search research articles
Contact Us
Filters
Showing results (11-20 of 24) with videos related to
Page
of 3
Sort By:
Leukemia & Lymphoma
|
June 1, 2013
Neem leaf extract induces cell death by apoptosis and autophagy in B-chronic lymphocytic leukemia cells
Kasyapa S Chitta, A Nazmul H Khan, Noreen Ersing, et al.
British Journal of Haematology
|
January 29, 2014
The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs
Aneel Paulus, Aisha Masood, Kena C Miller, et al.
Leukemia & Lymphoma
|
November 8, 2011
Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma
Sikander Ailawadhi, Jeff Miecznikowski, Dan P Gaile, et al.
British Journal of Haematology
|
October 21, 2011
Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response
Asher A Chanan-Khan, Kasyapa Chitta, Noreen Ersing, et al.
British Journal of Haematology
|
May 11, 2011
A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients
Taimur Sher, Sikander Ailawadhi, Kena C Miller, et al.
Journal for Immunotherapy of Cancer
|
February 9, 2025
Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry
Daniel J Landsburg, Matthew J Frigault, Michael Heim, et al.
Blood Advances
|
June 24, 2025
Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL
Rakesh Awasthi, Stephan A Grupp, Edward R Waldron, et al.
Nature Medicine
|
October 6, 2020
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
Reinhard Dummer, Celeste Lebbé, Victoria Atkinson, et al.
Leukemia & Lymphoma
|
July 21, 2012
Development and characterization of a novel human Waldenström macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute - Waldenström Macroglobulinemia 1
Kasyapa S Chitta, Aneel Paulus, Sikander Ailawadhi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 14, 2022
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for <i>BRAF</i> V600-Mutant Unresectable or Metastatic Melanoma
Reinhard Dummer, Georgina V Long, Caroline Robert, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 24) with videos related to
Sort By:
Page
of 3
Leukemia & Lymphoma
|
June 1, 2013
Neem leaf extract induces cell death by apoptosis and autophagy in B-chronic lymphocytic leukemia cells
Kasyapa S Chitta, A Nazmul H Khan, Noreen Ersing, et al.
British Journal of Haematology
|
January 29, 2014
The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs
Aneel Paulus, Aisha Masood, Kena C Miller, et al.
Leukemia & Lymphoma
|
November 8, 2011
Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma
Sikander Ailawadhi, Jeff Miecznikowski, Dan P Gaile, et al.
British Journal of Haematology
|
October 21, 2011
Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response
Asher A Chanan-Khan, Kasyapa Chitta, Noreen Ersing, et al.
British Journal of Haematology
|
May 11, 2011
A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients
Taimur Sher, Sikander Ailawadhi, Kena C Miller, et al.
Journal for Immunotherapy of Cancer
|
February 9, 2025
Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry
Daniel J Landsburg, Matthew J Frigault, Michael Heim, et al.
Blood Advances
|
June 24, 2025
Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL
Rakesh Awasthi, Stephan A Grupp, Edward R Waldron, et al.
Nature Medicine
|
October 6, 2020
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
Reinhard Dummer, Celeste Lebbé, Victoria Atkinson, et al.
Leukemia & Lymphoma
|
July 21, 2012
Development and characterization of a novel human Waldenström macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute - Waldenström Macroglobulinemia 1
Kasyapa S Chitta, Aneel Paulus, Sikander Ailawadhi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 14, 2022
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for <i>BRAF</i> V600-Mutant Unresectable or Metastatic Melanoma
Reinhard Dummer, Georgina V Long, Caroline Robert, et al.
Page
of 3